[Sustained remission with allogeneic peripheral blood stem cell transplantation and subsequent maintenance therapy with dasatinib in a patient with myeloblastic crisis of imatinib-resistant CML].
Rinsho Ketsueki
; 54(3): 279-83, 2013 03.
Article
in Ja
| MEDLINE
| ID: mdl-23676643
ABSTRACT
A 45-year-old man with chronic myelogenous leukemia (CML) in the chronic phase was treated with imatinib mesylate (IM). Although partial cytogenetic response (CyR) was obtained in 3 months, the patient exhibited back pain after treatment with IM for 5 months. He was diagnosed with myeloblastic crisis of CML with 30% blasts in the bone marrow. An extramedullary tumor with a diameter of 5-cm was found adjacent to the pancreatic head. Mutation analysis of the bcr/abl chimeric gene was negative. After the treatment with dasatinib (140 mg/day) for 40 days, complete CyR was obtained by bone marrow examination and the extramedullary tumor shrunk resulting in partial response on computed tomography. Allogeneic peripheral blood stem cell transplantation (allo-PBSCT) was performed from his HLA-DR one locus-mismatched sister. He has been in molecular remission for 24 months after allo-PBSCT and maintenance therapy with dasatinib has been administered. Dasatinib was tolerable without severe adverse events before and after allo-PBSCT in this case.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pyrimidines
/
Thiazoles
/
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
Drug Resistance, Neoplasm
/
Peripheral Blood Stem Cell Transplantation
/
Protein Kinase Inhibitors
Type of study:
Diagnostic_studies
Limits:
Humans
/
Male
/
Middle aged
Language:
Ja
Journal:
Rinsho Ketsueki
Year:
2013
Document type:
Article
Affiliation country:
Japan